TOREMIFENE CITRATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOREMIFENE CITRATE (TOREMIFENE CITRATE).
Nonsteroidal estrogen receptor antagonist; binds to estrogen receptors (ER) with high affinity, competitively inhibiting estrogen binding and exerting antiestrogenic effects. Also possesses weak estrogenic agonist activity.
| Metabolism | Primarily hepatic via CYP3A4 to N-desmethyltoremifene; also undergoes N-oxide formation. Excreted mainly in feces (75%) and urine (20%). |
| Excretion | Primarily fecal (biliary excretion) as metabolites; approximately 10% renal |
| Half-life | About 5 days for the parent compound; clinical context: steady-state achieved in ~4 weeks |
| Protein binding | >99.5% bound to albumin |
| Volume of Distribution | 580-800 L (approximately 8-12 L/kg); indicates extensive tissue distribution |
| Bioavailability | Oral: approximately 100% (well absorbed) |
| Onset of Action | Oral: within weeks for estrogen receptor antagonism; clinical response may take several weeks |
| Duration of Action | Prolonged due to long half-life; clinical effects persist weeks after discontinuation |
| Molecular Weight | 405.96 Da (as free base; toremifene citrate may vary) |
60 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for any degree of renal impairment |
| Liver impairment | Contraindicated in Child-Pugh class B or C; avoid use |
| Pediatric use | Safety and efficacy not established; no standard pediatric dosing |
| Geriatric use | No specific dose adjustment; monitor for increased adverse effects due to age-related changes in clearance |
| 1st trimester | Contraindicated due to known teratogenicity; may cause fetal harm. Reports of fetal abnormalities similar to diethylstilbestrol. |
| 2nd trimester | Contraindicated due to risk of fetal toxicity and potential for adverse effects on fetal development. |
| 3rd trimester | Contraindicated; may interfere with pregnancy completion and cause fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for TOREMIFENE CITRATE (TOREMIFENE CITRATE).
| Placental transfer | Toremifene and its metabolites cross the placenta in animal studies and are expected in humans. Degree of transfer is significant. |
| Breastfeeding | Excretion into human milk is unknown. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy and for at least 2 months after the last dose. |
■ FDA Black Box Warning
None
| Serious Effects |
PregnancyHistory of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism)Known hypersensitivity to toremifene or any excipientConcomitant use with warfarin or other coumarin anticoagulants
| Precautions | Prolongation of QT interval, especially in patients with electrolyte disturbances or concurrent QT-prolonging drugs, Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism), Endometrial hyperplasia and uterine malignancies due to estrogenic activity, Fetal harm if used during pregnancy, Hepatic impairment, Hypercalcemia in patients with bone metastases |
| Food/Dietary | Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing toremifene exposure. No other significant dietary restrictions. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Toremifene citrate is an antiestrogen; limited human data. In animals, fetal resorptions and developmental delays at doses similar to human exposure. FDA Pregnancy Category D. Avoid in pregnancy; potential for fetal harm, especially in first trimester. Use only if clearly needed. |
| Fetal Monitoring | Monitor LFTs, CBC, and serum calcium periodically. In pregnancy, assess fetal development via ultrasound if inadvertent exposure. Tumor response evaluation. No specific fetal monitoring required if not pregnant. |
| Fertility Effects | May suppress ovulation due to antiestrogenic effects; can impair fertility in women. Reversible upon discontinuation. Use of contraception recommended during treatment and for 2 months after last dose. No data on male fertility. |
| Clinical Pearls | Toremifene is a selective estrogen receptor modulator (SERM) used in metastatic breast cancer. It is metabolized via CYP3A4; inhibitors (e.g., ketoconazole) increase levels, inducers (e.g., rifampin) decrease levels. Monitor for QT prolongation, especially in patients with electrolyte disturbances or on other QT-prolonging drugs. Contraindicated in patients with a history of thromboembolic events. Toremifene has a long half-life (about 5 days) requiring steady-state monitoring. |
| Patient Advice | Take exactly as prescribed; do not stop or change dose without consulting your doctor. · Report any signs of blood clots (sudden chest pain, shortness of breath, leg swelling) or stroke (sudden numbness, weakness, trouble speaking). · Women of childbearing age must use effective contraception during treatment and for 2 months after stopping. · Avoid grapefruit and grapefruit juice as they may increase drug levels. · You may experience hot flashes, sweating, nausea, or vaginal discharge; notify your doctor if severe. · Regular blood tests (liver function, electrolytes) and ECG are required. |